SCHEDULE: Artelo Biosciences, Farb Reach Standstill Agreement

Artelo Biosciences and Daniel Farb's affiliates enter a standstill agreement, resolving director nominations and setting voting commitments.

Summary

• Daniel Stuart Farb and his affiliates (Farb Parties) entered into a letter agreement with Artelo Biosciences, Inc. on October 15, 2025.
• Farb irrevocably withdrew his nomination of director candidates for the Issuer's 2025 annual meeting of stockholders.
• The Farb Parties agreed to standstill restrictions and voting commitments during a 'Restricted Period'.
• Voting commitments include voting in favor of Board-nominated directors, against proposals to remove Board members, and in accordance with Board recommendations on other proposals.
• The Farb Parties are restricted from acquiring an ownership interest exceeding 8.0% of the outstanding shares.
• The agreement includes mutual non-disparagement obligations and a general mutual release of claims for matters arising on or prior to October 15, 2025.
• The Reporting Person also terminated the JFSA (Joint Filing Agreement) with Scott Pomfret on October 15, 2025.

Sentiment

Score: 7

Explanation: The agreement resolves a potential conflict and provides stability for the company's corporate governance, which is generally a positive development, though it also limits a significant shareholder's influence.

Positives

• Resolution of potential shareholder activism or a proxy contest, providing greater stability for the Board and management.
• Mutual release of claims reduces potential future litigation or disputes between the Farb Parties and the Issuer.
• Clear framework established for the relationship between a significant shareholder and the company, reducing uncertainty.

Negatives

• The Farb Parties' ability to influence corporate governance through director nominations or opposing Board recommendations is significantly restricted.
• The 8.0% ownership cap limits Daniel Farb's potential for increased stake and influence in the company.

Risks

• Potential for reduced independent shareholder oversight or challenge to management decisions from the Farb Parties due to voting commitments.
• The standstill agreement, while resolving immediate conflict, could be perceived by some as limiting shareholder democracy for this specific party.

Future Outlook

The filing outlines a framework for future interactions between Daniel Farb and Artelo Biosciences, particularly regarding corporate governance and shareholder voting, but does not provide a general business or financial outlook for the company.

Industry Context

This filing is a company-specific governance event, reflecting an agreement between a significant shareholder and the company's board, rather than a broader industry trend or development.

Corporate Governance

Legal Proceedings

• Mutual release of claims between the Farb Parties and the Issuer for any matter arising on or prior to October 15, 2025, indicating a resolution of potential past disputes.

Stakeholder Impact

• Shareholders: Reduced uncertainty regarding potential proxy contests, potentially leading to more stable stock performance. However, it also limits the influence of a significant shareholder.
• Management/Board: Increased stability and reduced pressure from a significant shareholder regarding director nominations and voting matters.

Next Steps

• The Farb Parties will adhere to the voting commitments and standstill restrictions during the Restricted Period.
• Artelo Biosciences will proceed with its 2025 annual meeting of stockholders without director nominations from Daniel Farb.

Key Dates

Keywords

Artelo Biosciences, Daniel Farb, Standstill Agreement, Shareholder Agreement, Corporate Governance, SEC Filing, Schedule 13D, Director Nomination, Voting Commitments, Beneficial Ownership